President Trump received mostly the same treatment as anyone would get for COVID-19, except for one experimental drug and the speed of his care. USA TODAY
Since President Donald Trump's COVID-19 diagnosis and hospitalization, health care professionals have voiced concernsregarding his broad medical regimen, which include steroid dexamethasone and Gilead's remdesivir. One treatment in particular, an experimental antibody drug from Regeneron Pharmaceuticals, is drawing criticism on social media.
"So it turns out the monoclonal antibodies Trump is on are from fetal stem cells. So Trump is being treated/saved with dead babies," reads a Twitter post shared on the Facebook group Dogs for Democracy.
The tweet goes on to call out Republicans,Supreme Court nominee Judge Amy Coney Barrettand anti-abortion activists.
Fact or fiction: We're fact checking the news and sending it to your inbox. Sign up to get that here.
A follow-up tweet containing a link to Regeneron's official position statement on stem cell research is provided as evidence for the claim.
While the Facebook post sharing the tweet has not received significant attention on the platform, it has gone viral on Twitter, gaining more than 347,000 likes and 107,000 retweets; similar tweets have also gone viral, including one from Rep.Ted Lieu, D-Calif.
USA TODAY has reached out to the administrators of the Dogs for Democracy Facebook group for further comment.
When the human body is invaded by a foreign pathogen be it a bacterium, virus, fungusor parasite Y-shaped proteins called antibodies are formed.They circulate through the body to sequesterand alert other immune chemicals and cells to destroy the pathogen, much like a search-and-destroy system.
The secret to fighting COVID-19 could be in recovered patients. Here's how antibodies could lead to a treatment for those fighting coronavirus. USA TODAY
Antibodies form the basis of "adaptive" immunity because they are genetically engineered, in a sense, by the body to recognize certain pathogens. This genetic engineering occurs within white blood cells called B cells, which manufactureand displaythe proteinson the cell surface, by way of genes rearranging like a set of numbers rearrangingto form different sequences or patterns.
Because this rearrangement is random, there is no telling what kind of specificity an antibody will exhibit or whether it will be biologically useful. Only if a B cell meets the right pathogen at the right time will it then activate and secrete its bespoke antibody. The activated B cell will also go on to clone itself through a process called clonal expansion, which helps mount an effective immune response by spawning vast quantities of antibodyand memory B cells (B cells which will remember the encounter for any future run-ins)as well as activating other immune cells.
Regeneron's experimental antibody "cocktail,"known as REGN-COV2, is a combination of two monoclonal antibodies (monoclonal referring to a specific B cell clone). These antibodies, REGN10933 and REGN10987, are engineered to lock on to SARS-CoV-2's spike protein, preventing it from interacting with its target on the host cell surface, the ACE2 receptor.
REGN-COV2 began its first clinical trial in June and is now in four late-stage clinical trials estimated to recruit at least11,000 participants combined, according to Genetic Engineering and Biotechnology News.
The antibody therapy has so far shown it's able to reduce SARS-CoV-2 viral loads and disease in experiments with golden hamsters and rhesus macaques. Findings presented last month from Regeneron's preliminary experiments in nonhospitalized, SARS-CoV-2 positive patients ranging from asymptomatic to moderate cases also showed reduced viral loads. However, more studies are needed to see how truly effective REGN-COV2 will be.
Fact check: Satirical post falsely claims Trump would be fine if he hadn't gotten tested
Fact check: Trump's hospital records, weight have not been released
Plasma cell producing antibodies, attacking coronavirus.(Photo: Floriana, Getty Images/iStockphoto)
Alexandra Bowie of Regeneron told news aggregation platform Heavy in an October email that REGN-COV2 was not made with human embryonic stem cells.
"This particular discovery program (REGN-COV2) did not involve human stem cells or ESCs," Bowie wrote.
The statement shared on Twitteris simply Regeneron's official position on stem cell research in general and bears no relation to, or explanation of, how REGN-COV2 is made. Bowie also confirmed this with Heavy.
It is unclear why Regeneron released an official statement in April. In an email to USA TODAY, Bowie did not clarify the timing, only alluding to the fact it was a common practice among pharmaceutical companies and that Regeneron sought transparency.
"Like many biopharma companies that conduct scientific research (see Pfizer, J&J, for instance), we have a general position statement on stem cell use,"Bowie said. "We share this and other similar statements in the interest of transparency and to help educate people on the steps we take to conduct our business responsibly."
While REGN-COV's monoclonal antibodies do appear to be derived from a B cell lineisolated from a human donor who recovered from SARS-CoV-2 and an immunized mouse engineered to have a human immune system,USA TODAY did note a fetal-derived cell linementioned in Regeneron's early research.
In supplementary material to a paper published in June in the journal Science, HEK293T cells an immortalized epithelial cell line (cellsnot normally immortal butaltered to be so via spontaneous mutation or in the lab)derived from embryonic kidney cellsobtained in 1972 were described as "briefly" used to create SARS-CoV-2-like viral particles to test mouse and human-derived antibodies against.
Bowie affirmed HEK293T cells were used but reiterated stem cells were not.
"This particular discovery program (REGN-COV2) did not involve human stem cells or ESCs," she wrote. "The293T cell line was originally derived from human embryonic kidney cells but is an immortalized epithelial cell so not a stem cell. These cells were transfected and used in production of a pseudoparticle that mimics the virus Spike protein and allowed us to test neutralization ability of our antibodies against the virus."
Fact check: Satirical post falsely claims COVID-19 is no worse than the flu and affects virtually no one
We rate this claim FALSE because it is not supported by our research.The experimental antibody therapy Trump received was not directly made from fetal or embryonic stem cells, rather antibodies obtained from SARS-CoV-2 human survivors and immunized mice engineered with a human immune system. Regeneron's official statement released in April, cited on Twitter as a basis for the claim, is a general position on stem cell research and is unrelated to how the antibody therapy is actually made. However, an embryonic-derived cellline, albeit not a stem cell, does appear to have been involved at least in the early stages of Regeneron's testing process, according to supplementary material published in June. The HEK293T cellsused are an immortalized cellline derived from embryonic kidney cells but are not stem cells themselves.
Thank you for supporting our journalism. You can subscribe to our print edition, ad-free app or electronic newspaper replica here.
Our fact check work is supported in part by a grant from Facebook.
This fact check is available at IFCNs 2020 US Elections FactChat #Chatbot on WhatsApp. Click here, for more.
Autoplay
Show Thumbnails
Show Captions
Read or Share this story: https://www.usatoday.com/story/news/factcheck/2020/10/08/fact-check-trumps-antibody-therapy-not-made-fetal-stem-cells/5901542002/
Continue reading here:
- Paralysed patient now able to walk as stem cell therapy shows promising results - WION - April 15th, 2024
- Andrew Steele Sees Aging as the Root of Disease - Worth - Worth Magazine - April 15th, 2024
- The astonishing effect of stem cell implants - as groundbreaking treatment 'transforms' life for those with brain damage ... - Daily Mail - April 15th, 2024
- Consumer Alert on Regenerative Medicine Products Including Stem Cells - FDA.gov - April 13th, 2024
- This Startup Wants To Be OpenAI Of Stem Cell Therapy, Targets $250B Market - Forbes - April 13th, 2024
- Brain-cell transplants are the newest experimental epilepsy treatment - MIT Technology Review - April 3rd, 2024
- Global Regenerative Medicine Market to Touch Valuation of USD 472.95 Billion by 2032, at 25.86% CAGR: Astute ... - Yahoo Finance - April 1st, 2024
- Explosive Growth Projected for Stem Cell Market, Expected to Surpass $37 Billion by 2030 As Revealed In New... - WhaTech - April 1st, 2024
- Integrating New Therapies With Autologous Stem Cell Transplant in Myeloma - Targeted Oncology - April 1st, 2024
- New tool provides researchers with improved understanding of stem cell aging in the brain - Medical Xpress - March 30th, 2024
- The ISSCR announces 2024 election results - EurekAlert - March 28th, 2024
- Exosomes and Stem Cells Are the Future of Anti-Aging - NewBeauty Magazine - March 28th, 2024
- Charles River Extends Gene Therapy Alliance with NUS Medicine - Contract Pharma - March 22nd, 2024
- Exciting opportunities in stem cell technology and regenerative biology in Indian healthcare industry - Express Healthcare - March 22nd, 2024
- Charles River Announces Extension of Gene Therapy Manufacturing Alliance with NUS Yong Loo Lin School of Medicine - Yahoo Finance - March 22nd, 2024
- Opinion: The revolutionary sickle cell therapies - MSN - March 22nd, 2024
- 10 Years of Kansas Regenerative Medicine Center - KSAL - March 22nd, 2024
- BioCardia and StemCardia Announce Biotherapeutic Delivery Partnership - Diagnostic and Interventional Cardiology - March 17th, 2024
- Cynata Therapeutics' breakthrough in regenerative medicine - Finance News Network - March 17th, 2024
- New Positive Data Presented on Briquilimab Conditioning in Patients with Fanconi Anemia - GlobeNewswire - March 17th, 2024
- Novel 3D stem cell therapy to treat critical limb ischaemia - Drug Target Review - March 15th, 2024
- Breaking Boundaries: Pharmicell's Bold Vision for Healthcare Transformation and Monumental Growth - The Worldfolio - March 15th, 2024
- CuSTOM Organoid Research Evolving From Tool to Treatment - Research Horizons - Research Horizons - March 15th, 2024
- BioCardia and StemCardia Announce Partnership to Deliver Cell-Gene Therapy for Remuscularization of Heart - Cath Lab Digest - March 15th, 2024
- Calidi Biotherapeutics and City of Hope Announce Funding from the California Institute for Regenerative Medicine ... - Business Wire - March 13th, 2024
- Iron restriction keeps blood stem cells young, researchers find - Phys.org - March 13th, 2024
- Vitamin A could have a key role in both stem cell biology and wound healing: Study - Medical Dialogues - March 9th, 2024
- Trends in Stem Cell Transplantation Refusal for Myeloma Treatment - Targeted Oncology - March 7th, 2024
- Stem Cell Therapy Market (CAGR) of 31.1%, Future of Market Size Emerging Technologies and their Impact on ... - Taiwan News - March 7th, 2024
- This Swedish startup wants to reduce the cost, and controversy, around stem cell production - TechCrunch - March 6th, 2024
- Advancing stem cell therapy: The regulatory process to get to clinical trials - The Economic Times - March 6th, 2024
- Transitioning from traditional surgical methods to the innovative use of stem cells - pharmaphorum - March 6th, 2024
- 'Mini organs' are grown from human stem cells taken during the late stages of pregnancy for the first time - m - Daily Mail - March 6th, 2024
- Stem cell transplant cures man of HIV and leukemia, one of five to achieve full remission - Fox 28 - March 3rd, 2024
- Stem Cell Therapy Market to Boost USD 137.5 Billion by 2034 and Projected to grow at 32.10% CAGR with increasing ... - Yahoo Finance - March 1st, 2024
- Studies expand use of stem cell therapies - WPLG Local 10 - March 1st, 2024
- Innovative therapy targets and destroys leukemia stem cells - News-Medical.Net - February 27th, 2024
- Unlocking the Potential of Stem Cells: The Medical Revolution of the Century - EIN News - February 27th, 2024
- Pelage Pharmaceuticals Announces $16.75M Series A Financing led by GV to Revolutionize Regenerative Medicine ... - Yahoo Finance - February 27th, 2024
- Say Her Name - Henrietta Lacks, The Real Mother Of Stem - Her Campus - February 27th, 2024
- California Man Free of HIV And Cancer in Astonishing Medical Recovery - ScienceAlert - February 25th, 2024
- $93 million for research into improved health for children, young people and the aged, medical devices, mental health ... - Department of Health - February 25th, 2024
- Stem Cells in Regenerative Medicine - PMC - National Center for ... - February 24th, 2024
- The Promise and Reality of Stem Cell Therapy: What You Need to Know - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy: A Beacon of Hope for Patients with Untreatable Conditions - Corporate Wellness Magazine - February 22nd, 2024
- Leading Experts in Stem Cell Therapy: A Global Overview - Corporate Wellness Magazine - February 22nd, 2024
- Can Stem Cells Help Reverse the Effects of Aging? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cell Therapy for Cancer: Hope on the Horizon? - Corporate Wellness Magazine - February 22nd, 2024
- Stem Cells and Autism: A Closer Look at Innovative Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Regrowth and Restoration: The Science Behind Stem Cell Therapy for Hair - Corporate Wellness Magazine - February 22nd, 2024
- Brain Recovery: The Role of Stem Cells in Stroke and Cerebral Palsy Treatments - Corporate Wellness Magazine - February 22nd, 2024
- Turning Back the Clock: The Science of Stem Cells in Anti-Aging - Corporate Wellness Magazine - February 22nd, 2024
- Insights into cellular therapies for cancer treatment - Drug Target Review - February 22nd, 2024
- The Role of Stem Cells in Rheumatoid Arthritis Recovery - Corporate Wellness Magazine - February 22nd, 2024
- Dr Ernesto Romeros vision transforms immunotherapy regenerative medicine into a global leader in stem cell treatment - Khaleej Times - February 22nd, 2024
- World-Renowned Doctors Leading the Way in Stem Cell Research and Treatment - Medical Tourism Magazine - February 20th, 2024
- Choosing the Best: A Guide to America's Premier Stem Cell Therapy Providers - Medical Tourism Magazine - February 20th, 2024
- Navigating Through the Possibilities of Stem Cell Treatment for Eye Disorders - Medical Tourism Magazine - February 20th, 2024
- Global Leaders in Stem Cell Therapy: Where Excellence Meets Innovation - Medical Tourism Magazine - February 20th, 2024
- Excellence in Stem Cell Treatment: How the US is Pioneering Global Healthcare Solutions - Medical Tourism Magazine - February 20th, 2024
- Clarifying Memory Loss Treatments: The Role of Stem Cells - Medical Tourism Magazine - February 20th, 2024
- Battling Inflammation: Stem Cell Therapy for Rheumatoid Arthritis - Medical Tourism Magazine - February 20th, 2024
- Digestive Health and Stem Cells: Treating Ulcerative Colitis and Crohn's Disease - Medical Tourism Magazine - February 20th, 2024
- Top Stem Cell Clinics in the USA: Pioneering Treatments for Chronic Conditions - Medical Tourism Magazine - February 20th, 2024
- Stem Cells and Autism: Understanding the Potential for Innovative Treatments - Medical Tourism Magazine - February 20th, 2024
- Stopping the awakening of sleeping Acute Myeloid Leukaemia stem cells to prevent disease relapse - University of Birmingham - February 20th, 2024
- City of Hope Achieves Ground Breaking Treatment for Blood Cancer and HIV - Medriva - February 18th, 2024
- Regenerative Medicine Market Size to Worth USD 95 Billion by 2032 - InvestorsObserver - February 18th, 2024
- North America Organoids Market Projected to Reach US$ 5.35 Billion by 2030, Riding on a CAGR of 21.5% - GlobeNewswire - February 18th, 2024
- Chinese team tests lung treatment that may be first to reverse COPD damage - South China Morning Post - February 15th, 2024
- Why leukemic stem cells not harmed by chemotherapy begin to grow and produce AML cells after treatment - Medical Xpress - February 15th, 2024
- Regenerative Medicine Market is Expected to Reach $49.0 Billion | MarketsandMarkets - Yahoo Finance - February 15th, 2024
- Study finds interleukin-24 enhances CAR-T cell therapy's effectiveness against cancer stem cells - News-Medical.Net - February 15th, 2024
- Oldest Patient 'Cured' of HIV Still in Remission 5 Years After Transplant for AML - Medpage Today - February 15th, 2024
- Drug used for cocaine addiction may pave way for new treatment of advanced colon cancer - EurekAlert - February 15th, 2024
- Hematopoietic Stem Cells and Their Role in Development and Disease Therapy - The Scientist - February 15th, 2024
- Biomedical Researcher Seeks to Improve Outcomes in Stem Cell Treatments - University of Arkansas Newswire - February 13th, 2024
- Top 3 grants in regenerative medicine: January 2024 - RegMedNet - February 13th, 2024
- Scalise returning to Washington next week with cancer in complete remission - The Hill - February 13th, 2024
- Unlocking the power of stem cell therapy - Drug Target Review - February 9th, 2024
Recent Comments